Cite
HARVARD Citation
Attiyeh, E. et al. (2016). Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program. Pediatric blood & cancer. 63 (2), pp. 276-286. [Online].